CompanyDeals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

CompanyDrug

Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China

CompanyDrug

D3 Bio’s KRAS Programs Advance: FDA Clears Phase I G12D Inhibitor D3S‑003 and Phase II G12C‑ERK Combo

CompanyDrug

Aidea’s ADC205 HIV Combo Gets NMPA Nod for Clinical Trials, Targeting $2.8B Market

CompanyMedical Device

Blue Sail’s Lithonic IVL System Wins CE Mark for Coronary Calcified Lesions

CompanyDrug

Shionogi’s Fetroja Wins China NMPA Approval for Complicated UTIs, Targets Resistant Gram‑Negative Infections

CompanyDrug

Chiesi’s Raxone Begins LHON Treatment in China, First World‑Approved Therapy

CompanyDeals

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal
CompanyDeals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

CompanyDrug

Novartis’s Ianalumab Wins FDA Breakthrough Therapy Designation for Sjögren’s Disease

CompanyDeals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

CompanyDrug

Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise